Stakes Are High for Regeneron's Eylea HD as Genentech's Vabysmo Continues to Gain Momentum, Prompting Doctors to Weigh Their Options Between Two Industry Titans, According to Spherix Global Insights
08 févr. 2024 15h17 HE
|
Spherix Global Insights
Exton, Pennsylvania, Feb. 08, 2024 (GLOBE NEWSWIRE) -- As Age-Related Macular Degeneration (AMD) Awareness Month unfolds, illuminating the visual challenges faced by millions of Americans with AMD,...
Rate of Switching from Regeneron’s Eylea to Genentech’s Vabysmo Doubled Over Past Year for Diabetic Macular Edema
01 nov. 2023 14h55 HE
|
Spherix Global Insights
Exton, Pennsylvania, Nov. 01, 2023 (GLOBE NEWSWIRE) -- As U.S. ophthalmologists increasingly embrace a wider array of treatment options, the landscape of the diabetic macular edema (DME) market has...
Anti-Vascular Endothelial Growth Factor Therapeutics market is expected to reach a US$13.1 Bn by 2032 at a CAGR 1% | According PMR
20 déc. 2022 08h10 HE
|
Persistence Market Research
New York, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Anti-Vascular Endothelial Growth Factor Therapeutics market is expected to reach a US$ 455 Mn by 2032 at a CAGR 1% | According PMR Anti-Vascular...
Coherus BioSciences to Report Second Quarter 2022 Financial Results on August 4th, 2022
28 juil. 2022 16h01 HE
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its second quarter 2022 financial results will be released after...
The Worldwide Anti-Vascular Endothelial Growth Factor Therapeutics Industry is Expected to Reach $13.3 Billion by 2030
03 juin 2022 06h58 HE
|
Research and Markets
Dublin, June 03, 2022 (GLOBE NEWSWIRE) -- The "Anti-Vascular Endothelial Growth Factor Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Product; By Disease; By Region; Segment...
Vista Partners Updates Coverage on Ohr Pharmaceutical, Inc.; Target Price $3.50
17 oct. 2012 09h15 HE
|
Vista Partners LLC
SAN FRANCISCO, CA--(Marketwire - Oct 17, 2012) - Vista Partners announced today that it has updated coverage on Ohr Pharmaceutical, Inc. (OTCBB: OHRP) ("The Company" or "OHR") with a twelve month...
Vista Partners Updates Coverage on Ohr Pharmaceutical, Inc.; Raises Target Price to $3.50
01 août 2012 09h15 HE
|
Vista Partners
SAN FRANCISCO, CA--(Marketwire - Aug 1, 2012) - Vista Partners announced today that it has updated coverage on Ohr Pharmaceutical, Inc. (OTCBB: OHRP) ("The Company" or "OHR") and raised its...
Vista Partners Initiates Coverage on Ohr Pharmaceutical, Inc.; Target Price $2.20
17 avr. 2012 09h15 HE
|
Vista Partners LLC
SAN FRANCISCO, CA--(Marketwire - Apr 17, 2012) - Vista Partners announced today that it has initiated coverage on Ohr Pharmaceutical, Inc. (OTCBB: OHRP) ("The Company" or "OHR") with a twelve month...